Regenxbio Inc
RGNX11.210USD
+0.040+0.36%
收盤 11/07, 16:00（美東）報價延遲15分鐘
567.44M總市值
虧損本益比TTM
關於 Regenxbio Inc 公司
REGENXBIO Inc. 是一家臨牀階段的生物技術公司，致力於通過基因治療的治癒潛力改善生活。該公司利用其專有的腺相關病毒 (AAV) 基因治療交付平臺 (NAV 技術平臺) 開發了一系列基因治療項目，以治療遺傳疾病。該公司專注於三個領域的內部開發管線：視網膜、神經肌肉和神經退行性疾病。其研究性 AAV 療法包括 ABBV-RGX-314、RGX-202 和 RGX-121。該公司正在與 AbbVie 合作開發 ABBV-RGX-314，以治療受溼性老年性黃斑變性、糖尿病視網膜病變 (DR) 和其他以視力喪失爲特徵的慢性視網膜疾病影響的大量患者羣體。該公司正在開發 RGX-202 來治療杜氏肌營養不良症 (Duchenne)。該公司正在開發 RGX-121 用於治療 II 型粘多糖貯積症 (MPS II)，這是一種進行性神經退行性溶酶體貯積症。
Regenxbio Inc簡介
公司代碼RGNX
公司名稱Regenxbio Inc
上市日期Sep 17, 2015
CEOMr. Curran M. Simpson
員工數量353
證券類型Ordinary Share
年結日Sep 17
公司地址9804 Medical Center Drive
城市ROCKVILLE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編20850
電話12405528181
網址https://regenxbio.com/
公司代碼RGNX
上市日期Sep 17, 2015
CEOMr. Curran M. Simpson
Regenxbio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.11K
-48.81%
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月8日 週六
更新時間: 11月8日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Redmile Group, LLC
9.43%
BlackRock Institutional Trust Company, N.A.
8.43%
The Vanguard Group, Inc.
6.59%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
其他
64.66%
持股股東
持股股東
佔比
Redmile Group, LLC
9.43%
BlackRock Institutional Trust Company, N.A.
8.43%
The Vanguard Group, Inc.
6.59%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
其他
64.66%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
33.94%
Investment Advisor
31.21%
Hedge Fund
12.74%
Individual Investor
7.62%
Research Firm
6.92%
Pension Fund
0.28%
Bank and Trust
0.26%
Family Office
0.26%
Private Equity
0.06%
其他
6.73%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Redmile Group, LLC
4.78M
9.45%
-19.06K
-0.40%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.27M
8.45%
+348.80K
+8.90%
Jun 30, 2025
The Vanguard Group, Inc.
3.42M
6.77%
-51.80K
-1.49%
Jun 30, 2025
Fox (Allan Mark)
2.90M
5.74%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.99M
5.91%
+38.82K
+1.32%
Jun 30, 2025
State Street Investment Management (US)
1.84M
3.65%
+777.55K
+72.93%
Jun 30, 2025
BlackRock Financial Management, Inc.
1.73M
3.43%
+637.97K
+58.36%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.61M
3.18%
+962.62K
+149.64%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.13M
2.23%
+21.57K
+1.95%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.12M
2.22%
-24.96K
-2.17%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
WisdomTree BioRevolution Fund
1.92%
iShares Neuroscience and Healthcare ETF
0.79%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Global X Genomics & Biotechnology ETF
0.51%
JPMorgan Fundamental Data Science Small Core ETF
0.32%
ALPS Medical Breakthroughs ETF
0.29%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
iShares Health Innovation Active ETF
0.09%
Fidelity Enhanced Small Cap ETF
0.08%
查看更多
WisdomTree BioRevolution Fund
佔比1.92%
iShares Neuroscience and Healthcare ETF
佔比0.79%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.68%
Global X Genomics & Biotechnology ETF
佔比0.51%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.32%
ALPS Medical Breakthroughs ETF
佔比0.29%
SPDR S&P Biotech ETF
佔比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.09%
iShares Health Innovation Active ETF
佔比0.09%
Fidelity Enhanced Small Cap ETF
佔比0.08%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
